Breaking News: SaniMed Partners with Former Medtronic Executive Gary Carruthers to Lead Asian MedTech Companies Into a New Era of U.S. Market Expansion!

SaniMed
Jun 5, 2025
3 min read

News Summary

SaniMed Science Group (USA) officially announced a long-term strategic partnership with global gastrointestinal (GI) medical technology expert and former Medtronic senior executive Gary Carruthers, appointing him as the Group’s Market Advisor.

With over 30 years of frontline experience in the U.S. medical technology industry, Gary Carruthers played a key role in bringing multiple innovative GI technologies—such as EndoFLIP—to commercial success across the U.S.

His joining will provide Asian, particularly Chinese, medical device innovators with full-chain professional consulting and hands-on support—spanning R&D, clinical validation, market access, and FDA approval. Together, BioTech (Shanghai) and SaniMed will empower Chinese MedTech companies to embark on a new journey toward global success.

Full Article

As the global medical device industry enters a new phase of deep integration and accelerated innovation, Asian—especially Chinese—high-growth MedTech enterprises are facing a historic “go-global” opportunity. Yet, bridging the entire chain from R&D → FDA approval → market promotion → clinical adoption remains the greatest challenge for Chinese companies seeking to achieve clinical recognition, market absorption, and reimbursement inclusion in the U.S.

At this critical juncture, SaniMed Science Group has introduced international industry leader Gary Carruthers as Market Advisor—ushering in a new chapter of U.S.–China MedTech collaboration and high-quality globalization.

Global Expert Joins, Redefining the Path of Globalization

Gary Carruthers is one of the most influential experts in the global GI medical device field, with more than 30 years of hands-on experience in the U.S. MedTech industry. During his tenure at Medtronic, the world’s largest medical device company, he held several key leadership positions—including National Clinical Education Manager, Principal Manager of Market Development, and National Accounts Director—and led the full commercial rollout of groundbreaking GI technologies such as EndoFLIP in the U.S.

Gary is renowned for his strategic foresight in driving end-to-end innovation—encompassing product design, clinical integration, FDA compliance, market access, and reimbursement pathways—while bridging efficient collaboration between clinicians, innovators, regulators, and payers.

He also played pivotal roles in multiple major Medtronic acquisitions, helping newly acquired companies integrate seamlessly into the U.S. healthcare ecosystem. With a deep understanding of U.S. regulatory and compliance frameworks, Gary brings a rare “FDA + Market + M&A” perspective—making him uniquely capable of guiding Chinese MedTech firms to overcome the “last mile” of global commercialization.

U.S.–China Dual Platform Collaboration: A Full-Stack Globalization Engine

This collaboration marks the formal integration of BioTech (Shanghai)—founded by Jim Wu —and SaniMed Science Group (USA) into a cross-border dual-platform ecosystem. Together, they are building a one-stop, full-chain service system that spans strategic consulting, FDA regulatory planning, clinical sales deployment, market access, and reimbursement strategy.

Jim Wu stated:

“Gary’s addition is not just about upgrading expertise—it’s about bringing executional excellence to the front line. We want to help Chinese MedTech innovators not only ‘go abroad,’ but truly ‘enter’ U.S. hospitals and operating rooms—achieving both clinical and commercial success.”

Global Resources Empowering Chinese Innovation: From ‘Going Out’ to ‘Going In’

In today’s international MedTech landscape, true globalization means more than exporting products—it demands comprehensive system-level capability: integrating R&D with clinical needs, co-developing physicians and markets, and penetrating regulatory and reimbursement systems.

Gary Carruthers’s partnership with SaniMed symbolizes a strategic leap for Chinese MedTech—from “Going Out” to “Going In”—connecting directly with top-tier global resources. Through the combined strengths of SaniMed and BioTech (Shanghai), Chinese innovators will gain stronger strategic guidance, faster market entry, and more reliable compliance support in the U.S.

This landmark collaboration between an international expert and a cross-border platform will accelerate the global expansion of China’s medical device industry—setting a new benchmark for high-quality, innovation-driven growth on the world stage.